Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.

已取消 20 由何曼慈发布于 2026/8/17 15:54:47

DOI:10.1182/blood.2025031858
作者：Lori S Muffly,Catherine J Lee,Arpita Gandhi,Ankur Varma,Bart L Scott,Sagar S Patel,Parveen Shiraz,Minyoung Youn,Chikako Yanagiba,Jeyakavitha Arulprakasam,Anne Le,Hye-Sook Kwon,Janel R Long-Boyle,Judit
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1182/blood.2025031858

American Society of Hematology (ASH)

Abstract：Briquilimab is a monoclonal antibody inhibiting stem cell factor (SCF) binding to CD117 (c-Kit). Based on preclinical data demonstrating the antibody clears hematopoietic stem and progenitor

应助信息

19小时前

Book学术机器人

2026/8/17 15:54:49 未找到该文献，机器人已退出，请等待人工下载

2026/8/17 15:54:47 Book学术AI机器人收到请求，开始寻找文献

2026/8/17 15:54:47 已向机器人发送请求

19小时前

何曼慈发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierLong-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study